Yukari Manabe, MD

CRS:

JHU

Role:

Investigators

Position:

Investigator

Email:

ymanabe@jhmi.edu

As part of the Center for Global Health, Dr. Manabe is interested in rapid diagnostics suitable for the resource-limited settings particularly in sub-Saharan Africa (SSA). She began her career working on the basic science aspects of tuberculosis (TB) immunopathogenesis in comparative animal models of infection, particularly latency, reactivation, and immune reconstitution inflammatory syndrome (IRIS) in the rabbit model within the Johns Hopkins Center for Tuberculosis Research. In 2007, she was seconded to the Infectious Diseases Institute (IDI) at Makerere College of Health Sciences as the Associate Medical Laboratory Director of the College of American Pathologists certified Makerere University-Johns Hopkins University Clinical Core Lab to study antiretroviral associated TB and IRIS. She then became the Head of Research at the IDI in 2008 until 2012 where she built research capacity and infrastructure for training Ugandan investigators. Her research has focused on accuracy testing of various rapid, point-of-care diagnostics for HIV and related infectious diseases of clinical importance in SSA. She is also interested in studying the impact of various diagnostic interventions on disease detection and patient outcomes.

Dr. Yukari Manabe obtained her undergraduate degree from Yale University and her M.D. from Columbia University College of Physicians and Surgeons. After completing both her residency in Internal Medicine and fellowship in Infectious Diseases at Johns Hopkins Hospital, she joined the faculty in 1999.

  • NWCS 408, parent study A5274

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

A5384: A Phase II, Randomized, Open-Label Trial of a...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Read More